REGULATORY PERSPECTIVE FOR GENE THERAPY PRODUCTS IN THE USA, EU AND JAPAN AND FUTURE ASPECTS
DOI:
https://doi.org/10.22159/ijpps.2024v16i6.50806Keywords:
Gene therapy products, Medical treatments, Genetic expressions, Regulatory considerations, Regulatory landscapeAbstract
Gene Therapy Products (GTPs) hold immense promise in revolutionizing medical treatments by altering genetic expressions to address various diseases. This study gives a summary of gene therapy products and their prospective uses, their historical development and several treatment options, as an in-depth exploration of the regulatory considerations for GTPs in the United States of America (USA), European Union (EU), and Japan, along with insights into future aspects of this field. A comprehensive discussion follows detailing the regulatory landscape and approval pathways in the USA, EU, and Japan. Programs that are exclusive to each area, such as PRIME (Priority Medicines) in the EU, USA's RMAT (Regenerative Medicines Advanced Therapy) designation and the Sakigake system in Japan are examined. Milestone meetings, approval requirements, and specific regulatory guidelines for GTPs in each region are also thoroughly covered. A list of approved GTPs and a glimpse into the future of the field. Anticipated trends include increasing investments, challenges related to production costs, expansion of manufacturing capabilities, and regulatory updates. The various regulatory strategies in each area and their efforts to balance patient access and safety will have a big impact on GTPs marketed in the future. Japan is well-positioned to maintain it’s as a global leader in regenerative medicine and cell treatments because of its favourable regulatory environment and government backing.
Downloads
References
What is gene therapy? In: FDA. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy [Last accessed on 25 Jul 2023]
Nhlbi. Genetic therapies-benefits and risks. NHLBI, NIH. Available from: https://www.nih.gov/health/genetic-therapies/benefits-risks [Last accessed on 15 Aug 2023]
The cost of sequencing a human genome. Available https://www.genome.gov/about-genomics/fact-sheets/sequencing-human-genome-cost [Last accessed on 07 Aug 2023]
Celec P, Gardlik R. Gene therapy using bacterial vectors. Front Biosci (Landmark Ed). 2017 Jan 1;22(1):81-95. doi: 10.2741/4473, PMID 27814603.
Razi Soofiyani SR, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L. Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull. 2013;3(2):249-55. doi: 10.5681/apb.2013.041, PMID 24312844.
How to navigate global regulatory frameworks and expedited programs for gene therapy development in the U. S., EU, and Japan>premier research. Available from: https://premier-research.com/blog-how-to-navigate-global-regulatory-frameworks-expedited-programs-for-gene-therapy-development-in-the-u-s-eu-japan [Last accessed on 15 Aug 2023]
Fast track designation request performance. In: FDA. Available from: https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/fast-track-designation-request-performance [Last accessed on 25 Jul 2023]
Breakthrough therapy. In: FDA. Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy [Last accessed on 25 Jul 2023]
Vaggelas A, Seimetz D. Expediting drug development: FDA’s new regenerative medicine advanced therapy designation. Ther Innov Regul Sci. 2019 May 1;53(3):364-73. doi: 10.1177/2168479018779373, PMID 29895180.
Designating an orphan product: drugs and biological products. In: FDA. Available from: https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products [Last accessed on 15 Aug 2023]
Heard JM, Vrinten C, Schlander M, Bellettato CM, Van Lingen C, Scarpa M. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network. Orphanet J Rare Dis. 2020 Jan 6;15(1):3. doi: 10.1186/s13023-019-1280-5, PMID 31907071.
Risk evaluation and mitigation strategies | REMS. In: FDA. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems [Last accessed on 15 Aug 2023]
Postmarketing requirements and commitments: reports. In: FDA. Available from: https://www.fda.gov/drugs/postmarket-requirements-and-commitments/postmarketing-requirements-and-commitments-reports [Last accessed on 16 Aug 2023]
Eichler HG, Pignatti F, Schwarzer Daum B, Hidalgo Simon A, Eichler I, Arlett P. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021 May 1;109(5):1212-8. doi: 10.1002/cpt.2083, PMID 33063841.
Eichler HG, Pignatti F, Schwarzer Daum B, Hidalgo Simon A, Eichler I, Arlett P. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021 May 1;109(5):1212-8. doi: 10.1002/cpt.2083, PMID 33063841.
Sakurai A. Pharmaceuticals and Medical Devices Agency regenerative medicine and gene therapy in Japan Pharmaceuticals and Medical Devices Agency (PMDA)/Q5A(R2) EWG Deputy Topic Leader (MHLW/PMDA); 2013.
PRIME: priority medicines | European Medicines Agency. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines [Last accessed on 25 Jul 2023]
PDF. Gene therapy. Principles and potential applications. Available from: https://www.researchgate.net/publication/11647636_gene_therapy_principles_and_potential_applications
Azuma K. Regulatory landscape of regenerative medicine in Japan. Curr Stem Cell Rep. 2015 Jun 1;1(2):118-28. doi: 10.1007/s40778-015-0012-6.
Maeda D, Yamaguchi T, Ishizuka T, Hirata M, Takekita K, Sato D. Regulatory frameworks for gene and cell therapies in Japan. Adv Exp Med Biol. 2015 Sep 19;871:147-62. Available from: https://pubmed.ncbi.nlm.nih.gov/26374217 [Last accessed on 25 Jul 2023]
Tanaka M, Idei M, Sakaguchi H, Kato R, Sato D, Sawanobori K. Achievements and challenges of the Sakigake designation system in Japan. Br J Clin Pharmacol. 2021 Oct 1;87(10):4027-35. doi: 10.1111/bcp.14807, PMID 33694268.
Strategy of SAKIGAKE. Available from: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/140729-01.html [Last accessed on 25 Jul 2023]
Sato Y, Ono S. Regulatory environment and approvals in cell and gene therapy products between Japan, the USA, and the EU. Ther Innov Regul Sci. 2023 Mar 1;57(2):227-37. doi: 10.1007/s43441-022-00455-4, PMID 36112305.
Sato Y, Ono S. Regulatory environment and approvals in cell and gene therapy products between Japan, the USA, and the EU. Ther Innov Regul Sci. 2023 Mar 1;57(2):227-37. doi: 10.1007/s43441-022-00455-4, PMID 36112305.
Zhang J. Regulatory considerations to accelerate cell and gene therapy development; 2021.
OTP Type a meetings. In: FDA. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/otp-type-meetings [Last accessed on 16 Aug 2023]
Fda, Cder. Guidance for industry formal meetings between the FDA and sponsors or applicants; 2009. p. 301-796. Available from: https://www.fda.gov/cber/guidelines.htm [Last accessed on 13 Aug 2023]
Manufacturing changes and comparability for human cellular and gene therapy products. In: FDA. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/manufacturing-changes-and-comparability-human-cellular-and-gene-therapy-products [Last accessed on 25 Jul 2023]
Ema. Step. Committee for Medicinal Products for Human Use ICH S12 Guideline on nonclinical biodistribution considerations for gene therapy products ICH S12 Guideline on nonclinical biodistribution considerations for gene therapy products; 2023. Available from: www.europa.eu/contact [Last accessed on 25 Jul 2023]
Medicines Agency E. Committee for Medicinal Products for Human Use. In: ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products; 2021. Available from: https://www.ema.europa.eu/contact [Last accessed on 25 Jul 2023]
Maeda H. The current status and future direction of clinical research in Japan from a regulatory perspective. Front Med (Lausanne). 2021 Jan 13;8:816921. doi: 10.3389/fmed.2021.816921, PMID 35096908.
Moriyama Y. Clinical trial notifications and Clinical trial notifications and scientific consultation scientific consultation system in Japan system in Japan; 1994.
Provisional Translation. Ministry of health, labour and welfare questions and answers (q and a) on points to consider for ensuring the reliability in utilization of data from registry or medical information database in applications for marketing approval and re-examination for regenerative medical products; 2023.
Approved cellular and gene therapy products. In: FDA. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products [Last accessed on 25 Jul 2023]
PEI. Gene therapy medicinal products with a valid marketing authorisation- Paul-Ehrlich-institute. Available from: https://www.de/en/medicinal-products/atmp/gene-therapy-medicinal-products/gene-therapy-node.html [Last accessed on 25 Jul 2023]
Review reports: regenerative medical products. In: Pharmaceuticals and Medical Devices Agency. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html.
Cell and gene therapy manufacturing services market drivers and opportunities. Markets and Markets. Available from: https://www.marketsandmarkets.com/market-reports/cell-gene-therapy-manufacturing-services-market-180609441.html?gclid=CjwKCAjw5remBhBiEiwAxL2M94d_G161UicjoTkJ8yN703GLwEh0LdvS3aB_an30JX1G7qdsHCgAIhoCeFcQAvD_BwE [Last accessed on 07 Aug 2023]
The Cell and Gene Therapy Sector. In: A wave is coming–are we ready; 2023. Available from: https://invivo.com/IV146781/the-cell-and-gene-therapy-sector-in-2023-a-wave-is-coming--are-we-ready [Last accessed on 07 Aug 2023]
Cell and gene therapies for rare disorders treatment in Japan. Available https://www.delveinsight.com/blog/cell-and-gene-therapies-for-rare-disorders-treatment [Last accessed on 07 Aug 2023]
Published
How to Cite
Issue
Section
Copyright (c) 2024 BALASUBRAMANYA P. K., SANGITA MISHRA, M. P. VENKATESH
This work is licensed under a Creative Commons Attribution 4.0 International License.
